Death receptors, in particular DR5, are highly attractive targets of antitumor therapy. The major limitation to application of natural death receptor ligands (TRAIL) is their non-specific cytotoxicity against normal cells. Since TRAIL can also bind decoy receptors (DcR) and prevent induction of apoptosis, the search for new DR-specific ligands is a topical issue. In the present study, we used combinatorial phage display peptide libraries to select a panel of DR5-binding amino acid sequences. A comparative analysis of the selected peptides enabled identification of the consensus sequence responsible for binding to DR5. Integration of this motif into polypeptide cytotoxic agents may provide targeted elimination of malignantly transformed cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bremer E. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol. 2013;2013. ID 371854. doi: 10.1155/2013/371854.
Fulda S. Safety and tolerability of TRAIL receptor agonists in cancer treatment. Eur. J. Clin. Pharmacol. 2015;71(5):525-527.
Li B, Russell SJ, Compaan DM, Totpal K, Marsters SA, Ashkenazi A, Cochran AG, Hymowitz SG, Sidhu SS. Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. J. Mol. Biol. 2006;361(3):522-536.
Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Exp. Cell Res. 2010;316(6):887-899.
Park HH, Lo YC, Lin SC, Wang L, Yang JK, Wu H. The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu. Rev. Immunol. 2007;25:561-586.
Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene. 2007;26(25):3745-3757.
Vrielink J, Heins MS, Setroikromo R, Szegezdi E, Mullally MM, Samali A, Quax WJ. Synthetic constrained peptide selectively binds and antagonizes death receptor 5. FEBS J. 2010;277(7):1653-1665.
Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003;22(53):8628-8633.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 163, No. 3, pp. 367-371, March, 2017
Rights and permissions
About this article
Cite this article
Ukrainskaya, V.M., Stepanov, A.V., Belogurov, A.A. et al. Combinatorial Screening of Peptides, Specific Ligands of Death Receptor DR5. Bull Exp Biol Med 163, 381–384 (2017). https://doi.org/10.1007/s10517-017-3809-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-017-3809-8